Video

Legal & Compliance Impact On Speed In The Antibody Market

Source: Cytiva

In this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses audience questions concerning the impact of regulatory requirements on multi-specific antibodies’ path to market, and how biopharma legal and compliance professionals can expedite the journey.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Cytiva